AU2476200A - Ribozyme therapy for the treatment and/or prevention of restenosis - Google Patents

Ribozyme therapy for the treatment and/or prevention of restenosis

Info

Publication number
AU2476200A
AU2476200A AU24762/00A AU2476200A AU2476200A AU 2476200 A AU2476200 A AU 2476200A AU 24762/00 A AU24762/00 A AU 24762/00A AU 2476200 A AU2476200 A AU 2476200A AU 2476200 A AU2476200 A AU 2476200A
Authority
AU
Australia
Prior art keywords
restenosis
prevention
treatment
ribozyme therapy
ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24762/00A
Inventor
Jack R. Barber
Joan M. Robbins
Richard Tritz
Peter J. Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusol Inc
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of AU2476200A publication Critical patent/AU2476200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen
AU24762/00A 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis Abandoned AU2476200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11095498P 1998-12-04 1998-12-04
US60110954 1998-12-04
PCT/US1999/028772 WO2000032765A2 (en) 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis

Publications (1)

Publication Number Publication Date
AU2476200A true AU2476200A (en) 2000-06-19

Family

ID=22335836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24762/00A Abandoned AU2476200A (en) 1998-12-04 1999-12-06 Ribozyme therapy for the treatment and/or prevention of restenosis

Country Status (3)

Country Link
EP (1) EP1147189A2 (en)
AU (1) AU2476200A (en)
WO (1) WO2000032765A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781151B2 (en) * 1999-10-26 2005-05-12 Immusol Incorporated Ribozyme therapy for the treatment of proliferative skin and eye diseases

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6492173B1 (en) * 2001-08-01 2002-12-10 Isis Pharmaceuticals, Inc. Antisense inhibition of cyclin D2 expression
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
ATE457716T1 (en) 2002-12-30 2010-03-15 Angiotech Int Ag RELEASE OF ACTIVE INGREDIENTS FROM QUICK-GELLING POLYMER COMPOSITION
US8029984B2 (en) 2003-08-08 2011-10-04 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis and therapy
CA2603730A1 (en) * 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781151B2 (en) * 1999-10-26 2005-05-12 Immusol Incorporated Ribozyme therapy for the treatment of proliferative skin and eye diseases

Also Published As

Publication number Publication date
WO2000032765A2 (en) 2000-06-08
WO2000032765A9 (en) 2002-08-29
WO2000032765A3 (en) 2000-11-16
EP1147189A2 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
AU2212299A (en) Compositions and methods for the treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
ZA9810788B (en) Method and composition for the treatment and prevention of hyperuricemia
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
AU9016898A (en) Methods and compositions for treatment of restenosis
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU4136901A (en) Novel methods for the treatment and prevention of dizziness and pruritus
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
AU1556497A (en) Agents for the treatment and prevention of aids
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU1742200A (en) Prevention and treatment of amyloid-associated disorders
SG92610A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU3785497A (en) Drug for the prevention or treatment of pollakiuria and urinary incontinence
AU2139097A (en) Methods of treating or preventing sleep apnea
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2964199A (en) Prevention and treatment of adhesions
EP0733365A3 (en) Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase